Skip to main content
Clinical Trials/CTRI/2023/02/049628
CTRI/2023/02/049628
Not yet recruiting
Phase 3

A randomized, double blind, comparative clinical study to compare and evaluate Efficacy and Safety of the Candimilt® 500 vaginal capsules (Miltonia Health Science Ltd) containing Clotrimazole 500 mg and the original drug Canesten® vaginal tablets containing Clotrimazole 500 mg, Bayer AG, Germany in patients with vulvovaginal candidiasis

MILTONIA HEALTH SCIENCE LTD0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: B373- Candidiasis of vulva and vagina
Sponsor
MILTONIA HEALTH SCIENCE LTD
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
MILTONIA HEALTH SCIENCE LTD

Eligibility Criteria

Inclusion Criteria

  • 1\. Women with the symptoms of vulvovaginal candidiasis (based on symptoms and signs after speculum examination);
  • 2\. Age at least 18 years;
  • 3\. Capable of giving written informed consent;
  • 4\. Agree to no intercourse for 8 days from the day of beginning of treatment;
  • 5\. Agree not to douche or use any intra\-vaginal products during the study period (including tampons, medications and devices);
  • 6\. Non\-pregnant Female patients aged 18 years or more and clinically diagnosed with vulvovaginal candidiasis were included;
  • 7\. Capable of giving written informed consent and willing to follow the investigational study procedures and report AEs.
  • 8\. Subjects must not be on their menstrual period on the day of screening and do not anticipate their period to begin during treatment (3 days);
  • 9\. Subjects must be using an acceptable method of birth control, willing to refrain from sexual intercourse from the date of screening until the follow\-up visit (approximately 7 days later);
  • 10\. Willing to refrain from the use of any intravaginal/ vulvovaginal products (douches, spermicidal foams or gels, vaginal lubricants, etc) from the screening visit until the follow up visit;

Exclusion Criteria

  • 1\. Women will be excluded from the study if they are using or has used any topical or systemic medication, particularly antimicrobial agents over a 30\-day period prior to the start of the investigation;
  • 2\. Female patient has a positive pregnancy test at screening, is pregnant or lactating, or is planning to become pregnant during the study period;
  • 3\. Previously diagnosed with human immunodeficiency virus (HIV) infection, having visible vaginal or cervical mass suspected cancer, and within six weeks of post\-abortion or postpartum;
  • 4\. Women who are currently or who will require treatment with anticoagulants, lithium, disulfiram, or neuromuscular blocking agents;
  • 5\. Women are hypersensitive to clindamycin, clotrimazole or to any excipient in the drug formulation;
  • 6\. Female patients who are breastfeeding or intending to breast feed during study period;
  • 7\. Study will also exclude patients with history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition;
  • 8\. Patients with a history of seizure disorders;
  • 9\. Patients with renal impairment (S. Creatinine \> 1\.5 times the normal reference values)
  • 10\. Patients with hepatic impairment. \[SGOT, SGPT, S. Bilirubin (Total) \>1\.5 times the normal reference values;

Outcomes

Primary Outcomes

Not specified

Similar Trials